Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
1. INTRODUCTION
Ischemic heart disease is the leading cause of death worldwide. Despite not having accurate statistics, Latin America incurs the trend of an increase in mortality from cardiovascular disease; one of the probable causes is rapid urbanization that has been associated with greater exposure to cardiovascular risk1. It is known that the only
effective measure to preserve ventricular function and reduce mortality, reinfarction and stroke is the rapid opening of the culprit artery to reestablish coronary flow2.
Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age : Statistics from World Health Organisation and United Nations. Int J Cardiol [Internet]. 2013;168(2):934–45. DOI: http://dx.doi.org/10.1016/j.ijcard.2012.10.046. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23218570
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119–77. DOI: 10.1093/eurheartj/ehx393. Available from: https://academic.oup.com/eurheartj/article/39/2/119/4095042
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Oct 2018; 72(18):2231-2264. DOI: 10.1016/j.jacc.2018.08.1038. Epub 2018 Aug 25. Available from: https://pubmed.ncbi.nlm.nih.gov/30153967/
Sgarbossa EB, Investigators G-1. Electrocardiographic Diagnosis of Evolving Acute Myocardial Infarction in the Presence of Left Bundle-Branch Block. N Engl J Med. 1996; 334:481–7. DOI: 10.1056/NEJM199602223340801. Available from: https://www.nejm.org/doi/full/10.1056/nejm199602223340801
Widimsky P, Roháč F, Štásek J, Kala P, Rokyta R, Kuzmanov B, et al. Primary angioplasty in acute myocardial infarction with right bundle branch block: Should new onset right bundle branch block be added to future guidelines as an indication for reperfusion therapy? Eur Heart J. 2012;33(1):86–95. DOI: 10.1093/eurheartj/ehr291. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21890488
Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation. 2015;131(24):2143–50. DOI: 10.1161/CIRCULATIONAHA.114.014494. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26002889
Zeymer U, Hohlfeld T, Vom Dahl J, Erbel R, Münzel T, Zahn R, et al. Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE). Thromb Haemost. 2017;117(3):625–35. DOI: 10.1160/TH16-08-0650. Available from: https://www.thieme-connect.com/products/ejournals/abstract/10.1160/TH16-08-0650
James S, Åkerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157(4):599–605. DOI: 10.1016/j.ahj.2009.01.003. Available from: https://pubmed.ncbi.nlm.nih.gov/19332184/
Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet [Internet]. 2010;376(9748):1233–43. DOI: http://dx.doi.org/10.1016/S0140-6736(10)61088-4. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61088-4/fulltext
Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: The international randomised open-label ATOLL trial. Lancet. 2011;378(9792):693–703. DOI: 10.1016/S0140-6736(11)60876-3. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60876-3/ppt
Silvain J, Beygui F, Barthélémy O, Pollack C, Cohen M, Zeymer U, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: Systematic review and meta-analysis. BMJ. 2012;344(7844):16. DOI: 10.1136/bmj.e553. Available from: https://www.bmj.com/content/344/bmj.e553
Collet JP, Huber K, Cohen M, Zeymer U, Goldstein P, Pollack C, et al. A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL Trial). Am J Cardiol [Internet]. 2013;112(9):1367–72. DOI: https://www.ajconline.org/article/S0002-9149(13)01510-5/fulltext. Available from: https://www.ajconline.org/article/S0002-9149(13)01510-5/fulltext
Gierlotka M, Gasior M, Wilczek K. Reperfusion by Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction Within 12 to 24 Hours of the Onset of Symptoms ( from a Prospective National Observational Study [PL-ACS]). AJC [Internet]. 2011;107(4):501–8. DOI: http://dx.doi.org/10.1016/j.amjcard.2010.10.008. Available from: https://www.ajconline.org/article/S0002-9149(10)02091-6/fulltext
Madan M, Halvorsen S, Di Mario C, Tan M, Westerhout CM, Cantor WJ, et al. Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: A patient-level analysis of the randomized early routine invasive clinical trials. JACC Cardiovasc Interv. 2015;8(1):166–74. DOI: 10.1016/j.jcin.2014.09.005. https://pubmed.ncbi.nlm.nih.gov/25616922/
Abdel-Qadir H, Yan AT, Tan M, Borgia F, Piscione F, Di Mario C, Halvorsen S, Cantor WJ, Westerhout CM, Scheller B, Le May MR, Fernandez-Aviles F, Sanchez PL, Lee DS, Goodman SG. Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis. Heart 2015; 101(19):1554–1561. DOI: 10.1136/heartjnl-2015-307815. Available from: https://pubmed.ncbi.nlm.nih.gov/26175478/
Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. N Engl J Med. 2013;368(15):1379–87. DOI: 10.1056/NEJMoa1301092. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1301092
Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infarction. N Engl J Med. 2005;353(26):2758–68. DOI: 10.1056/NEJMoa050849. Avialable from: https://www.nejm.org/doi/pdf/10.1056/NEJMoa050849
Investigators TC. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial. 2001;357:1385–90. DOI: 10.1016/s0140-6736(00)04560-8. Available from: https://pubmed.ncbi.nlm.nih.gov/11356434/
Prevention C, Eacpr R, Hoes AW, Ireland MC, Corra U, Uk CD, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology. 2016;2315–81. DOI: 10.1093/eurheartj/ehw106. Available from: https://pubmed.ncbi.nlm.nih.gov/27222591/
O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362–e425. DOI: 10.1161/CIR.0b013e3182742cf6. Available from: https://pubmed.ncbi.nlm.nih.gov/23247304/
Piegas LS, Timerman A, Feitosa GS, et al. V Diretriz da Sociedade Brasileira de cardiologia sobre tratameno do infarto agudo do miocárdio com supradesnivel do segmento ST. Arq brasileiros de Cardiologia, Volume 105, Nº 2, Suplemento 1, Agosto 2015.: Disponível em: http://publicacoes.cardiol.br/2014/diretrizes/2015/02_TRATAMENTO%20DO%20IAM%20COM%20SUPRADESNIVEL%20DO%20SEGMENTO%20ST.pdf
Pitt B, Poole-wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. ELITE II - Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure. Lancet. 2000;355:1582–7. DOI: 10.1016/s0140-6736(00)02213-3. Available from: https://europepmc.org/article/med/10821361
Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an Angiotension-converting-enzyme inhibitos, Ramipril, on cardiovascular Events in High-Risk Patients. N Engl J Med. 2000 Jan 20;342(3):145-53. Available from: https://pubmed.ncbi.nlm.nih.gov/10639539/
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Ph D, Werf F Van De, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003 Nov 13; 349(20):1893-906. Epub 2003 Nov 10. Doi: 10.1056/NEJMoa032292. Avaiable from: https://pubmed.ncbi.nlm.nih.gov/14610160/
Gara PTO, Kushner FG, Ascheim DD, Casey DE, Chung MK, Lemos JA De, et al. ACCF / AHA Guideline 2013 ACCF / AHA Guideline for the Management of ST-Elevation Myocardial Infarction A Report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. 2013;362–425. DOI: https://doi.org/10.1161/CIR.0b013e3182742cf6. Available from: https://www.ahajournals.org/doi/full/10.1161/CIR.0b013e3182742cf6
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.